Stay updated on Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial page.

Latest updates to the Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to reflect a new version (v2.15.0) and the addition of the study identifier 2125-RST-101, while significant details about the Phase 1b study and its inclusion and exclusion criteria have been removed.SummaryDifference33%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial page.